Nav: Home

Combining NSAIDs and TNFi may reduce radiographic progression in ankylosing spondylitis

June 14, 2018

The results of a cohort study presented at the Annual European Congress of Rheumatology (EULAR 2018) showed that, in patients with ankylosing spondylitis (AS) taking tumour necrosis factor (TNF) inhibitors, the addition of non-steroidal anti-inflammatory drugs (NSAIDs) was associated with significantly less radiographic progression in a dose-related manner at four years.1

When looking at specific NSAIDs, celecoxib in combination with TNF inhibitor use was associated with the greatest reduction in radiographic progression, which was significant at both two and four years.1

"Our results suggest that the use of TNF inhibitors and NSAIDs, particularly celecoxib, have a synergistic effect to slow radiographic progression in AS patients, particularly at higher doses," said Lianne Gensler, Associate Professor of Medicine, University of California, San Francisco (study author). "This is the first study to compare whether effects are comparable among different NSAIDs in this setting."

Ankylosing spondylitis is a chronic inflammatory disease that can be classified as being axial or non-axial (peripheral) disease, according to which joints in their body are affected. Over time, the joints can become damaged, a process referred to as radiographic or structural progression.

NSAIDs are first-line therapy for patients with AS. If patients have a poor response, contraindications or intolerance to NSAIDs, they may then be given TNF inhibitors.2 Current treatment practice is based on symptomatic relief, however there is also some evidence that NSAIDs slow radiographic progression if taken continuously.3 The evidence for the impact of TNF inhibitors on radiographic progression is unclear despite their good clinical efficacy.4,5 Many patients discontinue NSAIDs when they are put onto TNF inhibitors due to good symptom control,6 therefore there is very limited data on the impact of combined therapy on radiographic progression.

"Radiographic progression has an important bearing on patient mobility, as well as affecting their general well-being and day-to-day living," said Professor Robert Landewé, Chairperson of the Scientific Programme Committee, EULAR. "We welcome these results that support a potential disease modifying effect in patients with ankylosing spondylitis taking current therapies."

This prospective cohort study included 519 patients with AS who met the modified New York criteria with at least four years of clinical and radiographic follow up. The average age of participants was 41.4 years with an average symptom duration of 16.8 years, three quarters were male. NSAIDs were used in 66% of patients (half using an index below 50 and half above). TNF inhibitors were used in 46% of patients.1

After baseline measures, clinical and medication data were collected every six months, and radiographs performed every two years. Radiographic progression was measured using the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS). Statistical analysis which accounted for time-varying covariates was used to estimate the causal effect of TNF inhibitors and NSAIDs on radiographic progression. The analysis was adjusted for gender, race/ethnicity, education, symptom duration, enrolment year, number of years on TNF inhibitors, symptom duration at time of TNF inhibitor start, baseline mSASSS, ASDAS-CRP*, current smoking, and missed visit status.1

In patients taking TNFi, the addition of NSAID therapy was associated with less radiographic progression in a dose-related manner at four years. Mean difference in mSASSS between TNFi use and no TNFi use at four years was 0.50 (p=0.38), -1.24 (p<0.001), and -3.31 (p<0.001) for no NSAID, low NSAID, and high NSAID. When NSAID specific effects were examined, celecoxib in combination with TNFi use was associated with the greatest reduction in radiographic progression and this was significant at both two and four years. The mean difference in mSASSS between TNFi and no TNFi use for celecoxib was -3.98 (p<0.001) and -4.69 (p<0.001) at two and four years respectively.1
-end-
Abstract number: OP0198

* Ankylosing Spondylitis Disease Activity Score-C-reactive protein (ASDAS-CRP)

NOTES TO EDITORS

For further information on this study, or to request an interview with the study lead, please do not hesitate to contact the EULAR Press Office:

Email: eularpressoffice@ruderfinn.co.uk

Telephone: +44 (0) 20 7438 3084

Twitter: @EULAR_Press

YouTube: Eular Press Office

About Rheumatic and Musculoskeletal Diseases

Rheumatic and musculoskeletal diseases (RMDs) are a diverse group of diseases that commonly affect the joints but can affect any organ of the body. There are more than 200 different RMDs, affecting both children and adults. They are usually caused by problems of the immune system, inflammation, infections or gradual deterioration of joints, muscle and bones. Many of these diseases are long term and worsen over time. They are typically painful and Iimit function. In severe cases, RMDs can result in significant disability, having a major impact on both quality of life and life expectancy.7

About 'Don't Delay, Connect Today!'

'Don't Delay, Connect Today!' is a EULAR initiative that unites the voices of its three pillars, patient (PARE) organisations, scientific member societies and health professional associations - as well as its international network - with the goal of highlighting the importance of early diagnosis and access to treatment. In the European Union alone, over 120 million people are currently living with a rheumatic disease (RMD), with many cases undetected.8 The 'Don't Delay, Connect Today!' campaign aims to highlight that early diagnosis of RMDs and access to treatment can prevent further damage, and also reduce the burden on individual life and society as a whole.

About EULAR

The European League against Rheumatism (EULAR) is the European umbrella organisation representing scientific societies, health professional associations and organisations for people with RMDs. EULAR aims to reduce the burden of RMDs on individuals and society and to improve the treatment, prevention and rehabilitation of RMDs. To this end, EULAR fosters excellence in education and research in the field of rheumatology. It promotes the translation of research advances into daily care and fights for the recognition of the needs of people with RMDs by the EU institutions through advocacy action.

To find out more about the activities of EULAR, visit: http://www.eular.org.

References

1 Gensler LS, Gianfrancesco M, Weisman MH, et al. Combined effects of tumor necrosis factor inhibitors and NSAIDS on radiographic progression in ankylosing spondylitis. EULAR 2018; Amsterdam: Abstract OP0198.

2 van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978-991.

3 Wanders A, Heijde D, Landewe R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005;52:1756-65.

4 van der Heijde D, Landewé R, Baraliakos X, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum. 2008;58:3063-70.

5 Haroon N, Inman RD, Learch TJ, et al. The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2013;65:2645-2654.

6 Dougados M, Wood E, Combe B, et al. Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study. Arthritis Res Ther. 2014;16(6):481.

7 van der Heijde D, et al. Common language description of the term rheumatic and musculoskeletal diseases (RMDs) for use in communication with the lay public, healthcare providers and other stakeholders endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR). Annals of the Rheumatic Diseases. 2018;doi:10.1136/annrheumdis-2017-212565. [Epub ahead of print].

8 EULAR. 10 things you should know about rheumatic diseases fact sheet. Available at: https://www.eular.org/myUploadData/files/10%20things%20on%20RD.pdf [Last accessed April 2018].

European League Against Rheumatism

Related Ankylosing Spondylitis Articles:

New medication guidelines for rheumatic disease patients having joint replacement
In the first such collaboration of its kind, an expert panel of rheumatologists and orthopedic surgeons has developed guidelines for the perioperative management of anti-rheumatic medication in patients undergoing total hip or knee replacement.
Low-dose CT scanning improves assessment of ankylosing spondylitis patients
The results of a study presented today at the Annual European Congress of Rheumatology 2017 showed that low dose computed tomography is more sensitive than conventional radiographs (X-rays) in the monitoring of disease progression in patients with Ankylosing Spondylitis (AS).
Cutting-edge analysis reveals how different drugs interact with the same target
Osaka University-led researchers identified differences in how three drugs bind to tumor necrosis factor, a key mediator of inflammatory disease.
Combination of NSAIDs and TNF-inhibitors shows benefit for ankylosing spondylitis
A combination of nonsteroidal anti-inflammatory drugs and TNF-inhibitors may help slow down spine damage in ankylosing spondylitis, according to new research findings presented this week at the American College of Rheumatology Annual Scientific Meeting in Washington.
Statins may lower mortality risk in ankylosing spondylitis and psoriatic arthritis patients
Patients with ankylosing spondylitis or psoriatic arthritis who take statins may have as much as a 33 percent lower mortality risk, according to new research findings presented this week at the American College of Rheumatology Annual Scientific Meeting in Washington.
Women & long-term axial spondyloarthropathy patients at higher risk for manifestations
Gender and disease duration can help predict which axial spondyloarthritis patients will develop extra-articular manifestations such as uveitis, or inflammation of the eye, according to new research findings presented this week at the 2016 ACR/ARHP Annual Meeting in Washington.
Study shows swimming is an effective part of the treatment for fibromyalgia
A study performed by researchers at the Federal University of São Paulo shows swimming is as effective as walking to relieve pain and improve quality of life for patients with fibromyalgia, that experience chronic diffuse non-inflammatory pain in the musculoskeletal system deriving from malfunctioning of the system that transmits and modulates the transmission of nervous stimuli between the periphery of the body and the brain.
Facebook key to identifying thousands with inflammatory back pain
Facebook key to identifying thousands with inflammatory back pain.
Secukinumab in ankylosing spondylitis or psoriatic arthritis: Added benefit not proven
Drug manufacturer presented no relevant data and claimed no added benefit.
Global study reveals genes as major cause of inflammatory diseases
A world-first study led by Australia's Queensland University of Technology and Germany's Christian-Albrechts-University is likely to result in new treatments for five common and painful inflammatory diseases that affect millions of people around the world.

Related Ankylosing Spondylitis Reading:

Beating Ankylosing Spondylitis Naturally
by Dr. Scott A Johnson (Author)

Ankylosing Spondylitis: The Facts (The Facts Series)
by Muhammad Asim Khan (Author)

The Keystone Approach: Healing Arthritis and Psoriasis by Restoring the Microbiome
by Rebecca Fett (Author)

Ankylosing Spondylitis
by Michael H. Weisman (Author)

The Paleo Approach: Reverse Autoimmune Disease and Heal Your Body
by Sarah Ballantyne (Author), Robb Wolf (Foreword)

Ankylosing Spondylitis (Oxford American Rheumatology Library)
by Muhammad Asim Khan (Author)

Ankylosing Spondylitis Pyramid: The Lifestyle That Lets You Take Back Control
by Michael W. Smith, MD

Ankylosing Spondylitis: THE CURE
by ELEMENT 34

Ankylosing spondylitis e-chart: Quick reference guide

Ankylosing Spondylitis-Axial Spondyloarthritis
by Muhammad Asim Khan (Author)

Best Science Podcasts 2018

We have hand picked the best science podcasts for 2018. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Hacking The Law
We have a vision of justice as blind, impartial, and fair — but in reality, the law often fails those who need it most. This hour, TED speakers explore radical ways to change the legal system. Guests include lawyer and social justice advocate Robin Steinberg, animal rights lawyer Steven Wise, political activist Brett Hennig, and lawyer and social entrepreneur Vivek Maru.
Now Playing: Science for the People

#495 Earth Science in Space
Some worlds are made of sand. Some are made of water. Some are even made of salt. In science fiction and fantasy, planet can be made of whatever you want. But what does that mean for how the planets themselves work? When in doubt, throw an asteroid at it. This is a live show recorded at the 2018 Dragon Con in Atlanta Georgia. Featuring Travor Valle, Mika McKinnon, David Moscato, Scott Harris, and moderated by our own Bethany Brookshire. Note: The sound isn't as good as we'd hoped but we love the guests and the conversation and we wanted to...